"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 7 | 7 |
| 1996 | 1 | 5 | 6 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 10 | 10 |
| 2005 | 0 | 9 | 9 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 13 | 13 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 8 | 9 |
| 2012 | 0 | 6 | 6 |
| 2013 | 1 | 5 | 6 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 7 | 7 |
| 2016 | 0 | 6 | 6 |
| 2017 | 0 | 5 | 5 |
| 2018 | 0 | 6 | 6 |
| 2019 | 0 | 7 | 7 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.
-
ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors. Cancer Res. 2020 08 15; 80(16):3279-3291.
-
Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells. Apoptosis. 2020 04; 25(3-4):217-232.
-
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204.
-
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
-
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 01; 88:106271.
-
Gram-negative synergy and mechanism of action of alkynyl bisbenzimidazoles. Sci Rep. 2019 10 02; 9(1):14171.
-
Quercetin and Sodium Butyrate Synergistically Increase Apoptosis in Rat C6 and Human T98G Glioblastoma Cells Through Inhibition of Autophagy. Neurochem Res. 2019 Jul; 44(7):1715-1725.
-
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019 Jun; 54(6):2189-2199.
-
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.